Christopher Michael Lyons, a director at Sintx Technologies, Inc. (NASDAQ: SINT), has acquired 7,534 shares of the company’s stock in a transaction completed on March 2, 2024. The shares were purchased at an average price of $2.90, amounting to a total investment of $21,848.60. Following this acquisition, Lyons now directly owns 8,292 shares, which are valued at approximately $24,046.80. This purchase signifies a substantial increase in his holdings, reflecting a 993.93% rise in ownership.
The details of this transaction were disclosed in a filing with the Securities and Exchange Commission (SEC). The filing is accessible for public review, providing transparency regarding Lyons’ investment activities.
In the wake of this purchase, Sintx Technologies’ stock has shown slight movement. On March 3, 2024, shares of SINT traded up by 0.8%, reaching $2.77. During the trading session, 20,589 shares exchanged hands, which is lower than the average trading volume of 34,135 shares. The company’s recent performance indicates that its 50-day moving average stands at $3.28, while the 200-day moving average is at $3.67.
Sintx Technologies currently holds a market capitalization of $10.20 million and a price-to-earnings ratio of -0.49. Over the past year, the stock has fluctuated between a low of $1.71 and a high of $6.78, highlighting its volatility in the market.
Market Analysis and Analyst Ratings
Several research firms have recently provided insights into Sintx Technologies. On January 22, 2024, Weiss Ratings reiterated a “sell (e+)” rating for the company’s shares. In contrast, Ascendiant Capital Markets has revised its price target for Sintx from $25.00 to $16.00, assigning a “buy” rating in a report issued on December 8, 2023. Currently, one analyst has rated the stock as a “buy,” while another has issued a “sell” rating.
According to data from MarketBeat, Sintx Technologies has a consensus rating of “hold” with an average target price of $16.00. This mixed outlook reflects the varying perspectives on the company’s future performance.
About Sintx Technologies
Sintx Technologies, Inc. specializes in the development and manufacturing of silicon nitride-based biomaterials, particularly for surgical and implantable medical devices. The company’s proprietary silicon nitride ceramic is noted for its mechanical strength, biocompatibility, and intrinsic antimicrobial properties, making it a viable alternative to traditional metal and polymer materials used in implants.
Sintx focuses primarily on applications in spinal fusion, trauma fixation, and dental implantology—areas where device performance and long-term biological response are critical. Its core offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware, and trauma plates and screws.
As Sintx Technologies continues to innovate in the medical materials sector, the recent investment by Christopher Michael Lyons may indicate growing confidence in the company’s direction and potential market impact.
